Management of malignant pleural effusions

Drugs

Volumn 55, Issue 1, 1998, Pages 47-58

  Grossi, Francesco ^a   Pennucci, Maria Cristina ^a   Tixi, Lucia ^a   Cafferata, Mara A ^a   Ardizzoni, Andrea ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; BLEOMYCIN; SCLEROSING AGENT; TALC;

ADVANCED CANCER; ARTICLE; HUMAN; LIFE EXPECTANCY; PALLIATIVE THERAPY; PLEURA EFFUSION; PLEURODESIS; THORACOCENTESIS; THORAX DRAINAGE;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; PLEURA; PLEURAL EFFUSION, MALIGNANT;

EID: 0031974455     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855010-00004     Document Type: Article

References (87)

1. Chernow B, Sahn SA. Carcinomatous involvement of the pleura: an analysis of 96 patients. Am J Med 1977; 63: 695-702
2. Johnston WW. The malignant pleural effusion: a review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer 1985; 56 (4): 905-9
3. Fenton KN, Richardson JD. Diagnosis and management of malignant pleural effusions. Am J Surg 1995; 170: 69-74
4. Rusch VW, Harper GR. Pleural effusions in patients with malignancy. In: Roth JA, Ruckdeschel JC, Weisenburger TH, editors. Thoracic oncology. Philadelphia: WB Saunders, 1989: 594-605
5. Fusco V, Ardizzoni A, Merlo F, et al. Malignant pleural mesothelioma: multivariate analysis of prognostic factors on 113 patients. Anticancer Res 1993; 13: 683-90
6. Hausheer FH, Yarbro JW. Diagnosis and treatment of malignant pleural effusion. Semin Oncol 1985; 12: 54-75
7. Sahn SA. Malignant pleural effusions. Semin Respir Med 1987; 9 (1): 43-53
8. Tattersall M. Pleural effusion. Curr Opin Oncol 1992; 4: 642-6
9. Miles DW, Knight RK. Diagnosis and management of malignant pleural effusion. Cancer Treat Rev 1993; 19: 151-68
10. Lynch TJ. Management of malignant pleural effusions. Chest 1993; 103: 385S-9S
11. Keller SM. Current and future therapy for malignant pleural effusion. Chest 1993; 103: 63S-7S
12. Walker-Renard PB, Vaughan LM, Sahn SA. Chemical pleurodesis for malignant pleural effusions. Ann Intern Med 1994; 120: 56-64
13. Ruckdeschel JC. Management of malignant pleural effusions. Semin Oncol 1995; 22 (2 Suppl. 3): 58-63
14. Broaddus C, Staub N. Pleural liquid and protein turnover in health and disease. Semin Respir Med 1987; 9: 7-12
15. Perry MC, Yarbro JW. Toxicity of chemotherapy. Orlando (FL): Grune and Stratton, 1984
16. Anderson CB, Philpott GW, Ferguson TB. The treatment of malignant pleural effusion. Cancer 1974; 33: 916-22
17. Groth G, Gatzemeir U, Haussingen K, et al. Intrapleural palliative treatment of malignant pleural effusions with mitoxantrone versus placebo (pleural tube alone). Ann Oncol 1991; 2 (3): 213-5
18. Goff BA, Mueller PR, Muntz HG, et al. Small chest-tube drainage followed by bleomycin sclerosis for malignant pleural effusion. Obstet Gynecol 1993; 81: 993-6
19. Parker LA, Charnock GC, Delany DJ. Small bore catheter drainage and sclerotherapy for malignant pleural effusions. Cancer 1989; 64: 1218-21
20. Walsh FW, Alberts WM, Solomon DA, et al. Malignant pleural effusions: pleurodesis using a small-bore percutaneous catheter. South Med J 1989; 82: 963-5, 972
21. Martin N, Bains MS, Beattie EJ. Indications for pleurectomy in malignant pleural effusions. Cancer 1975; 35: 734-8
22. Harvey JC, Erdman CB, Beattie EJ. Early experience with videothoracoscopic hydrodissection pleurectomy in the treatment of malignant pleural effusion. J Surg Oncol 1995 Aug; 59 (4): 243-5
23. Waller DA, Morritt GN, Forty J. Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion. Chest 1995 May; 107 (5): 1454-6
24. Reich H, Beattie EJ, Harvey JC. Pleuroperitoneal shunt for malignant pleural effusions: a one-year experience. Semin Surg Oncol 1993 Mar-Apr; 9 (2): 160-2
25. Vargas FS, Wang NS, Lee HM, et al. Effectiveness of bleomycin in comparison to tetracycline as pleural sclerosing agent in rabbits. Chest 1993; 104: 1582-4
26. Rusch VW, Figlin R, Goodwin D, et al. Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group Trial. J Clin Oncol 1991; 9: 313-9
27. Oshimi K, Kano S, Takaku F, et al. Augmentation of mouse natural killer cell activity by a streptococcal preparation OK-432. J Natl Cancer Inst 1980; 65: 1265-70
28. Bayly TC, Kisner DL, Sybert A, et al. Tetracycline and quinacrine in the control of malignant pleural effusions: a randomized trial. Cancer 1978; 41 (3): 1188-92
29. Gupta N, Opfell RW, Padova J, et al. Intrapleural bleomycin versus tetracycline for control of malignant pleural effusion: a randomised study [abstract]. Proc Annu Meet Am Soc Clin Oncol 1980; 21: 366
30. Zaloznik AJ, Oswald SG, Langin M. Intrapleural tetracycline in malignant pleural effusions: a randomized study. Cancer 1983; 51 (4): 752-5
31. Leahy BC, Honeybourne D, Brear SG, et al. Treatment of malignant pleural effusions with intrapleural corynebacterium parvum or tetracycline. Eur J Resp Dis 1985; 66 (1): 50-4
32. Fentiman IS, Rubens RD, Hayward JL. A comparison of intracavitary talc and tetracycline for the control of pleural effusions secondary to breast cancer. Eur J Cancer Clin Oncol 1986; 22 (9): 1079-81
33. Kessinger A, Wigton RS. Intracavitary bleomycin and tetracycline in the management of malignant pleural effusions: a randomized study. J Surg Oncol 1987; 36: 81-3
34. Landvater L, Hix WR, Mills M, et al. Malignant pleural effusion treated by tetracycline sclerotherapy: a comparison of single vs repeated instillation. Chest 1988; 93 (6): 1196-8
35. Ruckdeschel JC, Moores D, Lee JY, et al. Intrapleural therapy for malignant pleural effusions: a randomized comparison of bleomycin and tetracycline. Chest 1991; 100: 1528-35
36. Evans TRJ, Stein RC, Pepper JR, et al. A randomised prospective trial of surgical against medical tetracycline pleurodesis in the management of malignant pleural effusions secondary to breast cancer. Eur J Cancer 1993; 29A (3): 316-9
37. Loutsidis A, Bellenis I, Argiriou M, et al. Tetracycline compared with mechlorethamine in the treatment of malignant pleural effusions: a randomized trial. Respir Med 1994 Aug; 88 (7): 523-6
38. Emad A, Rezaian GR. Treatment of malignant pleural effusions with a combination of bleomycin and tetracycline. Cancer 1996; 78: 2498-501
39. Kefford RF, Woods RL, Fox RM, et al. Intracavitary adriamycin, nitrogen mustard and tetracycline in the control of malignant effusions: a randomized study. Med J Aust 1980; 2 (8): 447-8
40. Light RW, O'Hare VS, Moritz TE, et al. Intrapleural tetracycline for the prevention of recurrent spontaneous pneumothorax: results of a Department of Veterans Affairs cooperative study. JAMA 1990; 264: 2224-30
41. Antony VB, Rothfuss KJ, Godbey SW, et al. Mechanism of tetracycline-hydrochloride-induced pleurodesis: tetracycline-hydrochloride-stimulated mesothelial cells produce a growth-factor-like activity for fibroblasts. Am Rev Respir Dis 1992; 146: 1009-13
42. Kitamura S, Sugiyama Y, Izumi T, et al. Intrapleural doxycycline for control of malignant pleural effusion. Curr Ther Res 1981; 30: 515-21
43. Muir JF, Defouilloy C, Ndarurinze S, et al. The use of intrapleural dosycycline by lavage and drainage in recurrent malignant pleural effusions. Rev Mal Respir 1987; 4/1: 29-33
44. Mansson T. Treatment of malignant pleural effusion with doxycycline. Scand J Infect Dis 1988; 20 Suppl. 53: 29-34
45. Robinson LA, Fleming WH, Galbraith TA. Intrapleural doxycycline control of malignant pleural effusions. Ann Thorac Surg 1993 May; 55 (5): 1115-21
46. Heffner JE, Standerfer RJ, Torstveit J, et al. Clinical efficacy of dosycycline for pleurodesis. Chest 1994; 105 (6): 1743-7
47. Seaton KG, Patz Jr EF, Goodman PC, Palliative treatment of malignant pleural effusions: value of small-bore catheter thoracostomy and doxycycline sclerotherapy. Am J Roentgenol 1995; 164/3: 589-91
48. Hatta T, Tsubota N, Yoshimura M, et al. Intrapleural minocycline for postoperative air leakage and control of malignant pleural effusion. Kyobu Geka 1990; 43 (4): 283-6
49. Bogliolo GV, Lerza R, Bottino GB, et al. Regional pharmacokinetic selectivity of intrapleural cisplatin. Eur J Cancer 1991; 27 (7): 839-42
50. Los G, Mutsaers PHA, Van der Vijgh WJF, et al. Direct diffusion of cis-diamminedichloroplatinum (II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 1989 Jun 15; 49: 3380-4
51. Paladine W, Cunningham TJ, Spouto R, et al. Intracavitary bleomycin in the management of malignant effusions. Cancer 1976; 38 (5): 1903-8
52. Bitran JD, Brown C, Desser RK, et al. Intracavitary bleomycin for the control of malignant effusions. J Surg Oncol 1981; 16 (3): 273-7
53. Ostrowski MJ. An assessment of the long-term results of controlling the reaccumulation of malignant effusions using intracavitary bleomycin. Cancer 1986; 57: 721-7
54. Hillerdal G, Kiviloog J, Nou E, et al. Corynebacterium parvum in malignant pleural effusion: a randomized prospective study. Eur J Respir Dis 1986; 69 (3): 204-6
55. Ostrowski MJ, Priestman TJ, Houston RF, et al. A randomized trial of intracavitary bleomycin and Corynebacterium parvum in the control of malignant pleural effusions Radiother Oncol 1989; 14 (1): 19-26
56. Hamed H, Fenliman IS, Chaudary MA, et al. Comparison of intracavitary bleomycin and talc for control of pleural effusions secondary to carcinoma of the breast. Br J Surg 1989; 76: 1266-7
57. Ostrowski MJ. Intracavitary therapy with bleomycin for the treatment of malignant pleural effusions. J Surg Oncol Suppl 1989; 1: 7-13
58. Moffet MJ, Ruckdeschel JC. Bleomycin and tetracycline in malignant pleural effusions: a review. Semin Oncol 1992; 19 (2 Suppl. 5): 59-62
59. Koldsland S, Svennevig JL, Lehne G, et al. Chemical pleurodesis in malignant pleural effusions: a randomised prospective study of mepacrine versus bleomycin. Thorax 1993 Aug; 48 (8): 790-3
60. Hartman DL, Gaither JM, Kesler KA, et al. Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions. J Thorac Cardiovasc Surg 1993; 105 (4): 743-7
61. Saka H, Shimokata K, Watanabe A, et al. Randomized comparison of OK-432 and bleomycin in intrapleural therapy for malignant pleural effusions [abstract]. Proc Annu Meet Am Soc Clin Oncol 1994; 13: A1555
62. Ferdoutsis E, Bouros D, Meletis G, et al. A comparative study of intrapleural instillation of bleomycin vs alpha2-interferon in the control of malignant pleural effusions [abstract]. Eur Respir J 1994; 7 Suppl. 18: 412s
63. Maiche AG, Virkkunen P, Kontkanen T, et al. Bleomycin and mitoxantrone in the treatment of malignant pleural effusions. Am J Clin Oncol 1993; 16 (1): 50-3
64. Morrison MC, Mueller PR, Lee MJ, et al. Sclerotherapy of malignant pleural effusion through sonographically placed small-bore catheters. Am J Roentgenol 1992; 158: 41-3
65. Deasai, Figueredo A. Intracavitary doxorubicin in malignant effusions [letter]. Lancet 1979; 1: 872
66. Masuno T, Kishimoto S, Ogura T, et al. A comparative trial of LC9018 plus doxorubicin and doxorubicin alone for the treatment of malignant pleural effusion secondary to lung cancer. Cancer 1991; 68: 1495-500
67. Ike O, Shimizu Y, Hitomi S, et al. Treatment of malignant pleural effusions with doxorubicin hydrochloride-containing poly (L-lactic acid) microspheres. Chest 1991; 99 (4): 911-5
68. Torsten U, Opri F, Weitzel H. Local therapy of malignant pleural effusion with mitoxantrone. Anticancer Drugs 1992; 3 (1): 17-8
69. Morales M, Exposito MC. Intrapleural mitoxantrone for the palliative treatment of malignant pleural effusions. Support Care Cancer 1995; 3 (2): 147-9
70. Bjermer L, Gruber A, Sue Chu M, et al. Effects of intrapleural mitoxantrone and mepacrine on malignant pleural effusion: a randomised study. Eur J Cancer 1995 Dec; 31A (13-4): 2203-8
71. Markman M, Cleary S, Pfeifle C, et al. Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma. Cancer 1986; 58: 18-21
72. Pfeifle CE, Howell SB, Markman M. Intracavitary cisplatin chemotherapy for mesothelioma. Cancer Treat Rep 1985; 69: 205-7
73. Rosso R, Rimoldi R, Salvati F, et al. Intrapleural natural beta interferon in the treatment of malignant pleural effusions. Oncology 1988; 45: 253-6
74. Goldman CA, Skinnider LF, Maksymiuk AW. Interferon instillation for malignant pleural effusions. Ann Oncol 1993; 4: 141-5
75. Yasumoto K, Ugura T. Intrapleural application of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer: a multi-institutional cooperative study. Biotherapy 1991; 3 (4): 345-9
76. Viallat JR, Boutin C, Rey F, et al. Intrapleural immunotherapy with escalating doses of interleukin-2 in metastatic pleural effusions: Cancer 1993; 71: 4067-71
77. Li DJ, Wang YR, Tan XY, et al. A new approach to the treatment of malignant effusion. Chin Med J (Engl) 1990 Dec; 103 (12): 998-1002
78. Chapes SK, Haskill S. Role of Corynebacterium parvum in the activation of peritoneal macrophages: II. Identification of distinguishable anti-tumor activities by macrophage subpopulations. Cell Immunol 1983; 76 (1): 49-57
79. Stephen K, Chapes SK, Haskill S. The role of Corynebacterium parvum in the activation of peritoneal macrophages. Cell Immunol 1982; 70: 65-75
80. Luh KT, Yang PC, Kuo SH, et al. Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer: a randomized trial. Cancer 1992; 69: 674-9
81. Fentiman IS, Rubens RD, Hayward JL. Control of pleural effusions in patients with breast cancer: a randomised trial. Cancer 1983; 52: 737-9
82. Biuchanna A, Chastre J, Gaudichet A, et al. Acute pneumonitis with bilateral pleural effusion after talc pleurodesis. Chest 1989; 86: 795-7
83. Mejer J, Mortensen KM, Hansen HH. Mepacrine hydrochloride in the treatment of malignant pleural effusion: a controlled randomized trial. Scand J Respir Dis 1977; 58 (6): 319-23
84. Bartal AH, Gazitt Y, Zidan G, et al. Clinical and flow cylometry characteristics of malignant pleural effusions in patients after intracavitary administration of methylpredrisolone acetate. Cancer 1991; 67: 3136-40
85. Rusch VW. The optimal treatment of malignant pleural effusions: a continuing dilemma. Chest 1991; 6: 1483-4
86. Belani CP, Einarson TR, Arikian SR, et al. Cost-effectiveness analysis of available sclerosing agents used for pleurodesis in the management of malignant pleural effusion (MPE) [abstract]. Proc Annu Meet Am Soc Clin Oncol 1995; 14: A892
87. Ray-Shee Lan, Sing Kai Lo, Ming-Lung Chuang, et al. Elastance of the pleural space: a predictor for the outcome of pleurodesis in patients with malignant pleural effusion. Ann Intern Med 1997; 126: 768-74